Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
E Kon, N Ad-El, I Hazan-Halevy… - Nature reviews clinical …, 2023 - nature.com
Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …
ongoing research area that started before these versatile nanoparticles were successfully …
Image-guided intratumoral immunotherapy: Developing a clinically practical technology
Immunotherapy has revolutionized the contemporary oncology landscape, with durable
responses possible across a range of cancer types. However, the majority of cancer patients …
responses possible across a range of cancer types. However, the majority of cancer patients …
Spatiotemporally controllable distribution of combination therapeutics in solid tumors by dually modified bacteria
L Wang, Z Cao, M Zhang, S Lin, J Liu - Advanced Materials, 2022 - Wiley Online Library
Methods capable of distributing antitumor therapeutics uniformly and durably throughout an
entire tumor would be of great significance in maximizing their treatment efficacy, but they …
entire tumor would be of great significance in maximizing their treatment efficacy, but they …
Maximizing response to intratumoral immunotherapy in mice by tuning local retention
Direct injection of therapies into tumors has emerged as an administration route capable of
achieving high local drug exposure and strong anti-tumor response. A diverse array of …
achieving high local drug exposure and strong anti-tumor response. A diverse array of …
High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo
SG Huayamares, MP Lokugamage, R Rab… - Journal of Controlled …, 2023 - Elsevier
Lipid nanoparticles (LNPs) are a clinically relevant way to deliver therapeutic mRNA to
hepatocytes in patients. However, LNP-mRNA delivery to end-stage solid tumors such as …
hepatocytes in patients. However, LNP-mRNA delivery to end-stage solid tumors such as …
[HTML][HTML] Therapeutic potential and limitations of curcumin as antimetastatic agent
P Dytrych, Z Kejík, J Hajduch, R Kaplánek… - Biomedicine & …, 2023 - Elsevier
Abstract Treatment of metastatic cancer is one of the biggest challenges in anticancer
therapy. Curcumin is interesting nature polyphenolic compound with unique biological and …
therapy. Curcumin is interesting nature polyphenolic compound with unique biological and …
[HTML][HTML] The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a
new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic …
new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic …
Advances of engineered extracellular vesicles-based therapeutics strategy
H Komuro, S Aminova, K Lauro… - Science and Technology …, 2022 - Taylor & Francis
Extracellular vesicles (EVs) are a heterogeneous population of lipid bilayer membrane-
bound vesicles which encapsulate bioactive molecules, such as nucleic acids, proteins, and …
bound vesicles which encapsulate bioactive molecules, such as nucleic acids, proteins, and …
Combined chemotherapy for triple negative breast cancer treatment by paclitaxel and niclosamide nanocrystals loaded thermosensitive hydrogel
D Zhao, C Hu, Q Fu, H Lv - European Journal of Pharmaceutical Sciences, 2021 - Elsevier
Triple negative breast cancer (TNBC) is the most dangerous subtype of breast cancer
accompanying by unfavorable prognosis due to lack of specific therapeutic targets …
accompanying by unfavorable prognosis due to lack of specific therapeutic targets …
Intratumorally anchored cytokine therapy
KD Wittrup, HL Kaufman, MM Schmidt… - Expert opinion on drug …, 2022 - Taylor & Francis
Introduction On-target, off-tumor toxicity severely limits systemic dosing of cytokines and
agonist antibodies for cancer. Intratumoral administration is increasingly being explored to …
agonist antibodies for cancer. Intratumoral administration is increasingly being explored to …